Stock Events

Stock Events

MyMD Pharmaceuticals 

$1.82
67
+$0+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-13.11MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MYMD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes with MyMD in the development of treatments for viral diseases, inflammatory and fibrotic diseases, which overlaps with MyMD's focus on immune-mediated diseases.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the immunology and oncology sectors, directly challenging MyMD's efforts in developing therapies for immune system diseases and cancer.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm focusing on novel therapies in areas like inflammation, which competes with MyMD's research into immune system modulation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer and immune system disorders, directly competing with MyMD's therapeutic areas.
Merck
MRK
Mkt Cap214.76B
Merck is known for its work in pharmaceuticals and vaccines, including treatments for immune system disorders, making it a competitor to MyMD.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and manufactures drugs and vaccines, including for autoimmune diseases, competing with MyMD's focus on immune system modulation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, including immune-mediated diseases, directly competing with MyMD's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on a broad range of healthcare areas, including advanced therapies in immunology and oncology, competing with MyMD.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology and rare diseases but also competes in the broader biopharmaceutical market against companies like MyMD.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals concentrates on treating the underlying causes of diseases in areas like cystic fibrosis, which involves modulation of the immune system, indirectly competing with MyMD.

About

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Show more...
CEO
Howard Yeaton
Employees
6
Country
US
ISIN
US62856X1028

Listings

F
DE
DQS.F
XNAS
US
QCLS
BOATS
BOATS
QCLS.BOATS
LSE
GB
0A8D.LSE

0 Comments

Share your thoughts

FAQ

What is MyMD Pharmaceuticals stock price today?▼
The current price of MYMD is $1.82 USD — it has increased by +0% in the past 24 hours. Watch MyMD Pharmaceuticals stock price performance more closely on the chart.
What is MyMD Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MyMD Pharmaceuticals stocks are traded under the ticker MYMD.
What were MyMD Pharmaceuticals earnings last quarter?▼
MYMD earnings for the last quarter are -5.14 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MyMD Pharmaceuticals revenue for the last year?▼
MyMD Pharmaceuticals revenue for the last year amounts to 0 USD.
What is MyMD Pharmaceuticals net income for the last year?▼
MYMD net income for the last year is -13.11M USD.
How many employees does MyMD Pharmaceuticals have?▼
As of April 01, 2026, the company has 6 employees.
In which sector is MyMD Pharmaceuticals located?▼
MyMD Pharmaceuticals operates in the Professional, Scientific, and Technical Services sector.
When did MyMD Pharmaceuticals complete a stock split?▼
The last stock split for MyMD Pharmaceuticals was on February 15, 2024 with a ratio of 1:30.
Where is MyMD Pharmaceuticals headquartered?▼
MyMD Pharmaceuticals is headquartered in West Deptford, US.